Pan-Cancer Analysis of Genomic Sequencing Among the Elderly

被引:8
|
作者
Wahl, Daniel R. [1 ]
Nguyen, Paul L. [3 ]
Santiago, Maria [4 ]
Yousefi, Kasra [4 ]
Davicioni, Elai [4 ]
Shumway, Dean A. [1 ]
Speers, Corey [1 ]
Mehra, Rohit [2 ]
Feng, Felix Y. [5 ]
Osborne, Joseph R. [6 ]
Spratt, Daniel E. [1 ]
机构
[1] Univ Michigan, Dept Radiat Oncol, 1500 E Med Ctr Dr,SPC 5010,UH B2C490, Ann Arbor, MI 48109 USA
[2] Univ Michigan, Dept Pathol, Ann Arbor, MI 48109 USA
[3] Dana Farber Canc Inst, Dept Radiat Oncol, Boston, MA 02115 USA
[4] GenomeDx Biosci, Vancouver, BC, Canada
[5] Univ Calif San Francisco, Dept Radiat Oncol, San Francisco, CA USA
[6] Mem Sloan Kettering Canc Ctr, Dept Radiol, 1275 York Ave, New York, NY 10021 USA
关键词
CELL LUNG-CANCER; OLDER PATIENTS; AGE; EXPERIENCE; DISCOVERY; MUTATIONS;
D O I
10.1016/j.ijrobp.2017.01.002
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: We hypothesized that elderly patients might have age-specific genetic abnormalities yet be underrepresented in currently available sequencing repositories, which could limit the effect of sequencing efforts for this population. Methods and Materials: Leveraging The Cancer Genome Atlas (TCGA) data portal, 9 tumor types were analyzed. The frequency distribution of cancer by age was determined and compared with Surveillance, Epidemiology, and End Results data. Using the estimated median somatic mutational frequency of each tumor type, the samples needed beyond TCGA to detect a 10% mutational frequency were calculated. Microarray data from a separate prospective cohort were obtained from primary prostatectomy samples to determine whether elderly-specific transcriptomic alterations could be identified. Results: Of the 5236 TCGA samples, 73% were from patients aged <70 years. Comparing the distribution of TCGA samples by age to the Surveillance, Epidemiology, and End Results data, patients <70 years were well represented across most tumor types, but patients aged 80 to 99 years were underrepresented in all cancers (median TCGA underrepresentation of 167%). All cancers (except for colorectal) contained enough samples to detect a 10% mutational frequency in patients aged <60 years. In contrast, no cancer type had enough samples for which a 10% mutational frequency could be detected in patients aged >= 80 years. To further interrogate whether elderly patients with cancer were likely to harbor age-specific molecular abnormalities, we accessed transcriptomic data from a separate, larger database of >2000 prostate cancer samples. That analysis revealed significant differences in the expression of 10 genes in patients aged >= 70 years compared with those <70 years, of which 7 are involved in androgen signaling and/or DNA repair. Conclusions: Elderly patients have been underrepresented in genomic sequencing studies. Our data suggest the presence of elderly-specific molecular alterations. Further dedicated efforts to understand the biology of cancer among the elderly will be important moving forward. (C) 2017 Elsevier Inc. All rights reserved.
引用
收藏
页码:726 / 732
页数:7
相关论文
共 50 条
  • [1] Pan-Cancer Analysis of the Genomic Alterations and Mutations of the Matrisome
    Izzi, Valerio
    Davis, Martin N.
    Naba, Alexandra
    CANCERS, 2020, 12 (08) : 1 - 21
  • [2] Pan-cancer analysis of fear of cancer recurrence among cancer survivors
    Adashek, J. J.
    Jordan, A.
    Redwine, L. S.
    Tyson, D. Martinez
    Thompson, Z.
    Pabbathi, S.
    ESMO OPEN, 2022, 7 (04)
  • [3] Pan-cancer analysis of tumor metabolic landscape associated with genomic alterations
    Choi, Hongyoon
    Na, Kwon Joong
    MOLECULAR CANCER, 2018, 17
  • [4] Pan-cancer analysis of tumor metabolic landscape associated with genomic alterations
    Hongyoon Choi
    Kwon Joong Na
    Molecular Cancer, 17
  • [5] Pan-cancer analysis of alternative splicing patterns and association to genomic aberrations
    Hayrynen, Sergei
    Nykter, Matti
    CANCER RESEARCH, 2016, 76
  • [6] Pan-cancer pharmacogenetics: targeted sequencing panels or exome sequencing?
    Tilleman, Laurentijn
    Heindryckx, Bjorn
    Deforce, Dieter
    van Nieuwerburgh, Filip
    PHARMACOGENOMICS, 2020, 21 (15) : 1073 - 1084
  • [7] Pan-cancer analysis of neoepitopes
    Gabriel N. Teku
    Mauno Vihinen
    Scientific Reports, 8
  • [8] Pan-cancer analysis of neoepitopes
    Teku, Gabriel N.
    Vihinen, Mauno
    SCIENTIFIC REPORTS, 2018, 8
  • [9] Pan-cancer genomic analyses uncover molecular drivers
    David Killock
    Nature Reviews Clinical Oncology, 2018, 15 : 263 - 263
  • [10] Comprehensive pan-cancer analyses of RAS genomic diversity
    Scharpf, Robert
    Riely, Gregory
    Awad, Mark
    Lenoue-Newton, Michele
    Ricciuti, Biagio
    Rudolph, Julia
    Raskin, Leon
    Park, Andrew
    Lee, Jocelyn
    Lovly, Christine
    Anagnostou, Valsamo
    CANCER RESEARCH, 2020, 80 (16)